BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33615973)

  • 1. Potential public health impact of a
    Huang L; Snedecor SJ; Balmer P; Srivastava A
    Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Collins JP; Crowe SJ; Ortega-Sanchez IR; Bahta L; Campos-Outcalt D; Loehr J; Morgan RL; Poehling KA; McNamara LA
    MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):345-350. PubMed ID: 38635488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
    Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K
    J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
    Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
    Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
    Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.
    Marshall GS; Fergie J; Presa J; Peyrani P
    Infect Dis Ther; 2022 Jun; 11(3):937-951. PubMed ID: 35357651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
    Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
    mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study.
    Welsch JA; Senders S; Essink B; Klein T; Smolenov I; Pedotti P; Barbi S; Verma B; Toneatto D
    Vaccine; 2018 Aug; 36(35):5309-5317. PubMed ID: 30061029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
    Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations.
    Huang L; Goren A; Lee LK; Li VW; Dempsey A; Srivastava A
    Hum Vaccin Immunother; 2020 Apr; 16(4):933-944. PubMed ID: 31634035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.
    Mbaeyi SA; Bozio CH; Duffy J; Rubin LG; Hariri S; Stephens DS; MacNeil JR
    MMWR Recomm Rep; 2020 Sep; 69(9):1-41. PubMed ID: 33417592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States.
    Ghaswalla PK; Bengtson LGS; Marshall GS; Buikema AR; Bancroft T; Schladweiler KM; Koep E; Novy P; Hogea CS
    Vaccine; 2021 Jan; 39(2):272-281. PubMed ID: 33309081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal vaccination: a discussion with all adolescents, whether college-bound or not.
    Alderfer JT; Moran MM; Srivastava A; Isturiz RE
    Postgrad Med; 2019 Nov; 131(8):551-554. PubMed ID: 31575310
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
    McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
    Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.
    Sáez-Llorens X; Beltran-Rodriguez J; Novoa Pizarro JM; Mensi I; Keshavan P; Toneatto D
    Hum Vaccin Immunother; 2018 May; 14(5):1161-1174. PubMed ID: 29601256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serogroup B meningococcal vaccination practice patterns on college campuses.
    Haimowitz R; Torres R; Caleb S; Thompson D; Smith A; Ciotoli C; Dannenbaum M; Fu LY
    Vaccine; 2020 Oct; 38(46):7350-7356. PubMed ID: 33010977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.